Genmab's Financial Calendar for 2009

• Press Release
• Source: Genmab A/S
• On 8:41 am EST, Wednesday December 10, 2008

COPENHAGEN, Denmark, Dec. 10, 2008 (GLOBE NEWSWIRE) -- Genmab A/S (NasdaqGS:GEN - News) announces its financial calendar for 2009 as follows:

  ------------------------------------------------------------------------
  EVENT                                         DATE
  ------------------------------------------------------------------------
  Publication of the Financial Statement        Tuesday, February 24, 2009
   Release for 2008
  ------------------------------------------------------------------------
  Publication of the Annual Report for 2008     Tuesday, March 17, 2009
  ------------------------------------------------------------------------
  Annual General Meeting 2009                   Wednesday, April 15, 2009
  ------------------------------------------------------------------------
  Publication of the Interim Report for the     Tuesday, May 12, 2009
   first quarter 2009
  ------------------------------------------------------------------------
  Publication of the Interim Report for the     Tuesday, August 18, 2009
   first half 2009
  ------------------------------------------------------------------------
  Publication of the Interim Report for the     Tuesday, November 10, 2009
   first nine months 2009
  ------------------------------------------------------------------------

Publication of the financial reports will be after market close on the date of the event.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words ``believe,'' ``expect,'' ``anticipate,'' ``intend'' and ``plan'' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section ``Risk Management'' in Genmab's Annual Report, which is available on http://www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law.

Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax-EGFr(tm); HuMax-IL8(tm); HuMax-TAC(tm); HuMax-HepC(tm); HuMax-CD38(tm); HuMax-CD32b(tm) and UniBody(r) are all trademarks of Genmab A/S.

Stock Exchange Release no. 56/2008

          Genmab A/S
          Helle Husted, Sr. Director, Investor Relations
          T: +45 33 44 77 30
          M: +45 25 27 47 13
          hth@genmab.com